Evidence map›Paper›PMID 27497264›Full record

ArticleJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2017

Identification of a combined biomarker for malignant transformation in oral submucous fibrosis.

Shadavlonjid Bazarsad, Xianglan Zhang, Ki-Yeol Kim, Rasika Illeperuma, Ruwan D Jayasinghe, Wanninayake M Tilakaratne, Jin Kim

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The combined assessment of p16Frontiers in oncology · 2024
    Article
  6. Review
  7. Review
  8. Circulating Vimentin Over-Expression in Patients with Oral Sub Mucosal Fibrosis and Oral Squamous Cell Carcinoma.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. A contemporary narrative review to guide molecular epidemiology of oral submucous fibrosis.International journal of molecular epidemiology and genetics · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. Oral submucous fibrosis: a contemporary narrative review with a proposed inter-professional approach for an early diagnosis and clinical management.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. Identification of a combined biomarker for malignant transformation in oral submucous fibrosis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Shadavlonjid BazarsadDepartment of Oral Pathology, Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, South Korea.
Xianglan ZhangDepartment of Oral Pathology, Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, South Korea.
Ki-Yeol KimDepartment of Oral Pathology, Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, South Korea.
Rasika IlleperumaDepartment of Medical Laboratory Science, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka.
Ruwan D JayasingheDepartment of Oral Medicine & Periodontology, Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka.
Wanninayake M TilakaratneDepartment of Oral Pathology, Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka.
Jin KimDepartment of Oral Pathology, Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, South Korea.
University of Peradeniya · LKYonsei University · KRMongolian National University · MNYonsei University College of Dentistry

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral submucous fibrosis (OSF) is a chronic progressive disease of the oral cavity that is considered a common potentially malignant disorder in South Asia. Areca nut chewing is the main etiological factor, but its carcinogenic mechanism has yet to be proven. The purpose of this study was to identify the useful biomarkers in predicting high-risk patients with OSF.

methodsThirty-six cases of OSF and six cases of normal oral mucosa (NOM) were used for this study. Immunohistochemical staining was performed for Ki67, cyclin D1, p16, p53, β-catenin, c-Jun, c-Met, and insulin-like growth factor II mRNA-binding protein 3 (IMP3). The expression patterns of NOM served as guidelines for the scoring system.

resultsThe expression of Ki67, cyclin D1, c-Met, IMP3, and β-catenin showed a significant difference between OSF and NOM samples. The combined biomarkers of Ki67 and p16 showed significantly different expression between the transformation and non-transformation groups. With discriminant analysis, we proposed a noble formula and cutoff value for predicting high-risk patients with OSF.

conclusionThe notable biomarkers in our present study were Ki67 and p16 showing significantly different expression levels between the transformation and non-transformation groups. With the identification of high-risk patients with OSF, we can expect to develop more intensive treatment modalities, leading to the reduction in cancer transformation rate from OSF.

Indexed as

AdultArecaBiomarkers, TumorBiopsyCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p16FemaleHumansImmunohistochemistryKi-67 AntigenMaleMiddle AgedMouth NeoplasmsOral Submucous FibrosisRisk FactorsBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Ki-67 Antigencombined biomarkersoral submucous fibrosisrisk assessmentsquamous cell carcinoma

Identifiers

PMID27497264
PMCPMC5516200
OpenAlexW2486638894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.